The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Sports
Taiwan's women's recurve team wins silver at World University Games
07/26/2025 11:48 AM - Sports
Taiwan shuttler advances to men's singles final at World University Games
07/26/2025 10:50 AM - Society
Extremely heavy rain alert issued in southern Taiwan
07/26/2025 10:41 AM - Society
Taiwan headline news
07/26/2025 10:16 AM - Politics
Voting starts to recall KMT legislators, Hsinchu mayor
07/26/2025 08:08 AM